Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168163 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
A Phase 2 study of Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8, sponsored by Academic and Community Cancer Research United.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 16
- Study locations
NCT05168163 is a Phase 2 study of Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8 that is actively recruiting participants, run by Academic and Community Cancer Research United. The registered enrollment target is 122 participants, above the 51-participant average among 14 other Stage III Hepatocellular Carcinoma AJCC v8 trials with a reported enrollment target (139% higher). The trial reports 16 study locations across 12 states.
The verdict
NCT05168163, a Phase 2 study of Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8, is actively recruiting participants, sponsored by Academic and Community Cancer Research United.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 16
- Study locations
Study Summary
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- DRUG Cabozantinib
- DRUG Lenvatinib
Study Locations (16)
Florida
- Mayo Clinic in Florida - Jacksonville
- Cleveland Clinic Weston Florida - Weston
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Carle Cancer Center NCI Community Oncology Research Program - Urbana
Michigan
- Michigan Cancer Research Consortium NCORP - Ann Arbor
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Wisconsin
- Froedtert and the Medical College of Wisconsin LAPS - Milwaukee
- Medical College of Wisconsin - Milwaukee
Arizona
- Mayo Clinic in Arizona - Scottsdale
Louisiana
- University Medical Center New Orleans - New Orleans
Minnesota
- Mayo Clinic in Rochester - Rochester
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05168163
The ClinicalTrials.gov registry entry for NCT05168163 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 14 other Stage III Hepatocellular Carcinoma AJCC v8 trials with a reported enrollment target (139% higher). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Stage III Hepatocellular Carcinoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT05168163 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT05168163 about?
NCT05168163 is a clinical study titled "Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer". This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymp...
What is the current status of trial NCT05168163?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2022-05-27. Estimated completion is 2026-12-31.
What conditions does trial NCT05168163 study?
This clinical trial studies the following conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma AJCC V8.
What interventions are being tested in trial NCT05168163?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Cabozantinib (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT05168163?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05168163 being conducted?
This trial has 16 study locations across Arizona, Florida, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Hepatocellular Carcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
RECRUITING · Phase 2
-
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
RECRUITING · Phase 2
-
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage III Hepatocellular Carcinoma AJCC v8
All registered trials for this condition
Stage IV Hepatocellular Carcinoma AJCC v8
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.